



Fig. S2. Effect of tralokinumab on interleukin (IL)-13-mediated secretion of CCL-17/TARC and CCL-22/MDC from peripheral blood mononuclear cells (PBMCs). Human PBMCs were cultured in presence of 0.8 nM (10 ng/ml) IL-13 and a wide concentration range of tralokinumab for 24 h. Protein levels (pg/ml) of CCL-17/TARC and CCL-2/MDC were measured in the supernatants.